Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
dc.contributor.author | Ramos, German. E. E. | |
dc.contributor.author | Caglevic, Christian | |
dc.contributor.author | Bulnes, Juan. F. F. | |
dc.contributor.author | Panay, Sergio. E. E. | |
dc.contributor.author | Zapata, Mario. I. I. | |
dc.contributor.author | Daniele, Andres J. | |
dc.contributor.author | Rodriguez, Manuel. E. E. | |
dc.date.accessioned | 2025-01-20T21:01:16Z | |
dc.date.available | 2025-01-20T21:01:16Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient. | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.3389/fcvm.2022.1060813 | |
dc.identifier.issn | 2297-055X | |
dc.identifier.uri | https://doi.org/10.3389/fcvm.2022.1060813 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/92848 | |
dc.identifier.wosid | WOS:000893774000001 | |
dc.language.iso | en | |
dc.revista | Frontiers in cardiovascular medicine | |
dc.rights | acceso restringido | |
dc.subject | Takotsubo (stress) cardiomyopathy | |
dc.subject | Afatinib | |
dc.subject | EGFR mutation | |
dc.subject | tyrosine kinase inhibition | |
dc.subject | NSCLC | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report | |
dc.type | artículo | |
dc.volumen | 9 | |
sipa.index | WOS | |
sipa.trazabilidad | WOS;2025-01-12 |